CEO & President of Intercept Pharmaceuticals Inc (ICPT, Financial) Mark Pruzanski bought 7,812 shares of ICPT on 04/09/2018 at an average price of $64 a share. The total cost of this purchase was $499,968.
Intercept Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need. Intercept Pharmaceuticals Inc has a market cap of $1.74 billion; its shares were traded at around $69.24 with and P/S ratio of 13.47.
CEO Recent Trades:
- CEO & President Mark Pruzanski bought 7,812 shares of ICPT stock on 04/09/2018 at the average price of $64. The price of the stock has increased by 8.19% since.
Directors and Officers Recent Trades:
- 10% Owner S.p.a. Genextra bought 390,625 shares of ICPT stock on 04/09/2018 at the average price of $64. The price of the stock has increased by 8.19% since.
- 10% Owner Francesco Micheli bought 390,625 shares of ICPT stock on 04/09/2018 at the average price of $64. The price of the stock has increased by 8.19% since.
- Director Keith Michael Gottesdiener bought 1,171 shares of ICPT stock on 04/09/2018 at the average price of $64. The price of the stock has increased by 8.19% since.
- Director Daniel Bradbury bought 7,812 shares of ICPT stock on 04/09/2018 at the average price of $64. The price of the stock has increased by 8.19% since.
For the complete insider trading history of ICPT, click here
.
